Literature DB >> 12857906

Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Chen-Fu Yang1, Tary Naguib, Su-Ju Yang, Eman Nasr, Jaume Jorba, Nahed Ahmed, Ray Campagnoli, Harrie van der Avoort, Hiroyuki Shimizu, Tetsuo Yoneyama, Tatsuo Miyamura, Mark Pallansch, Olen Kew.   

Abstract

From 1988 to 1993, 30 cases of poliomyelitis associated with poliovirus type 2 were found in seven governorates of Egypt. Because many of the cases were geographically and temporally clustered and because the case isolates differed antigenically from the vaccine strain, it was initially assumed that the cases signaled the continued circulation of wild type 2 poliovirus. However, comparison of sequences encoding the major capsid protein, VP1 (903 nucleotides), revealed that the isolates were related (93 to 97% nucleotide sequence identity) to the Sabin type 2 oral poliovirus vaccine (OPV) strain and unrelated (<82% nucleotide sequence identity) to the wild type 2 polioviruses previously indigenous to Egypt (last known isolate: 1979) or to any contemporary wild type 2 polioviruses found elsewhere. The rate and pattern of VP1 divergence among the circulating vaccine-derived poliovirus (cVDPV) isolates suggested that all lineages were derived from a single OPV infection that occurred around 1983 and that progeny from the initiating infection circulated for approximately a decade within Egypt along several independent chains of transmission. Complete genomic sequences of an early (1988) and a late (1993) cVDPV isolate revealed that their 5' untranslated region (5' UTR) and noncapsid- 3' UTR sequences were derived from other species C enteroviruses. Circulation of type 2 cVDPVs occurred at a time of low OPV coverage in the affected communities and ceased when OPV coverage rates increased. The potential for cVDPVs to circulate in populations with low immunity to poliovirus has important implications for current and future strategies to eradicate polio worldwide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857906      PMCID: PMC165252          DOI: 10.1128/jvi.77.15.8366-8377.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.

Authors:  P E Fine; I A Carneiro
Journal:  Am J Epidemiol       Date:  1999-11-15       Impact factor: 4.897

2.  Stopping poliovirus vaccination after eradication: issues and challenges.

Authors:  D J Wood; R W Sutter; W R Dowdle
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

3.  Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models.

Authors:  Z Yang; R Nielsen
Journal:  Mol Biol Evol       Date:  2000-01       Impact factor: 16.240

4.  Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Authors:  G V Gavrilin; E A Cherkasova; G Y Lipskaya; O M Kew; V I Agol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Developing and expanding contributions of the global laboratory network for poliomyelitis eradication, 1997-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-03-03       Impact factor: 17.586

7.  Preparation and characterization of encephalomyocarditis (EMC) virus.

Authors:  R R Rueckert; M A Pallansch
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

8.  Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China.

Authors:  H M Liu; D P Zheng; L B Zhang; M S Oberste; M A Pallansch; O M Kew
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel.

Authors:  L M Shulman; Y Manor; R Handsher; F Delpeyroux; M J McDonough; T Halmut; I Silberstein; J Alfandari; J Quay; T Fisher; J Robinov; O M Kew; R Crainic; E Mendelson
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

10.  Resolution of the pathways of poliovirus type 1 transmission during an outbreak.

Authors:  L M Shulman; R Handsher; C F Yang; S J Yang; J Manor; A Vonsover; Z Grossman; M Pallansch; E Mendelson; O M Kew
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

View more
  88 in total

1.  Multiplex PCR method for identifying recombinant vaccine-related polioviruses.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Ray Campagnoli; Christopher J Freeman; Nada Mishrik; Hong-Mei Liu; Mark A Pallansch; Olen M Kew
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

2.  RNA recombination plays a major role in genomic change during circulation of coxsackie B viruses.

Authors:  M Steven Oberste; Silvia Peñaranda; Mark A Pallansch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  High frequency of human enterovirus species C circulation in Madagascar.

Authors:  Mala Rakoto-Andrianarivelo; Dominique Rousset; Richter Razafindratsimandresy; Stéphane Chevaliez; Sophie Guillot; Jean Balanant; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region.

Authors:  Minetaro Arita; Shuang-Li Zhu; Hiromu Yoshida; Tetsuo Yoneyama; Tatsuo Miyamura; Hiroyuki Shimizu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Membrane adsorption with direct cell culture combined with reverse transcription-PCR as a fast method for identifying enteroviruses from sewage.

Authors:  D Papaventsis; N Siafakas; P Markoulatos; G T Papageorgiou; C Kourtis; E Chatzichristou; C Economou; S Levidiotou
Journal:  Appl Environ Microbiol       Date:  2005-01       Impact factor: 4.792

8.  Use of a multiple restriction fragment length polymorphism method for detecting vaccine-derived polioviruses in clinical samples.

Authors:  Natalia I Romanenkova; Sophie Guillot; Nadejda R Rozaeva; Radu Crainic; Maina A Bichurina; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

9.  Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China.

Authors:  Hong-Mei Liu; Du-Ping Zheng; Li-Bi Zhang; M Steven Oberste; Olen M Kew; Mark A Pallansch
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  High frequency and diversity of species C enteroviruses in Cameroon and neighboring countries.

Authors:  Serge Alain Sadeuh-Mba; Maël Bessaud; Denis Massenet; Marie-Line Joffret; Marie-Claire Endegue; Richard Njouom; Jean-Marc Reynes; Dominique Rousset; Francis Delpeyroux
Journal:  J Clin Microbiol       Date:  2012-12-19       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.